Primary biliary cholangitis patient analysis [whitepaper]

Primary biliary cholangitis (PBC) is a rare, chronic liver disease that impacts 58 out of every 100,000 women and 15 out of every 100,000 men in the United States. It typically progresses slowly, exhibiting no symptoms during the first several years — but in later stages, it can cause debilitating symptoms such as fatigue, itchiness, abdominal pain, swelling of the limbs, jaundice, osteoporosis, high cholesterol, and weight loss.

PBC occurs due to the injury of the small bile ducts in the liver, and can eventually lead to cirrhosis if these ducts are destroyed. The cause of PBC is unknown, and there is currently no cure, so many patients must be treated using symptom management and liver medications that prove to be ineffective for many. While PBC patients do tend to respond well to liver transplants, this is the last line of treatment due to the invasiveness of the procedure and long wait times.

Because of the significant symptoms and disheartening prognosis of PBC, there is a clear necessity to research better treatment options. In this whitepaper, we use data we gathered from our patient database to explore the demographics of PBC patients, and we put this information in context to help sponsors consider how study design can boost clinical trial enrollment and increase the success of future clinical trials. Interested in learning more?